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Summary
To date, there is a lack of long-term safety and efficacy data for iron chelation
therapy in transfusion-dependent patients with sickle cell disease (SCD). To
evaluate the long-term safety and efficacy of deferasirox (a once-daily oral
iron chelator), patients with SCD completing a 1-year, Phase II, randomized,
deferoxamine (DFO)-controlled study entered a 4-year extension, continuing
to receive deferasirox, or switching from DFO to deferasirox. Average actual
deferasirox dose was 19Æ4 ± 6Æ3 mg/kg per d. Of 185 patients who received at
least one deferasirox dose, 33Æ5% completed the 5-year study. The most
common reasons for discontinuation were withdrawal of consent (23Æ8%),
lost to follow-up (9Æ2%) and adverse events (AEs) (7Æ6%). Investigator-
assessed drug-related AEs were predominantly gastrointestinal [including
nausea (14Æ6%), diarrhoea (10Æ8%)], mild-to-moderate and transient in
nature. Creatinine clearance remained within the normal range throughout
the study. Despite conservative initial dosing, serum ferritin levels in patients
with ‡4 years deferasirox exposure significantly decreased by )591 lg/l (95%
confidence intervals, )1411, )280 lg/l; P = 0Æ027; n = 67). Long-term
deferasirox treatment for up to 5 years had a clinically acceptable safety
profile, including maintenance of normal renal function, in patients with
SCD. Iron burden was substantially reduced with appropriate dosing in
patients treated for at least 4 years.
Keywords: deferasirox, Exjade, oral iron chelator, sickle cell disease, iron
overload.
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Regular blood transfusion currently represents a supportive
therapy to manage the anaemia and vasculopathy associated
with sickle cell disease (SCD). In adults, aggressive transfu-
sion to treat and improve organ dysfunction is increasingly
used (National Institutes of Health NHLBI, 2002; Wun &
Hassell, 2009) and chronic transfusion therapy significantly
reduces the risk of primary and secondary stroke in paediatric
patients with SCD (Adams et al, 1998; Adams & Brambilla,
2005).
As the life expectancy and subsequent transfusion exposure
of patients with SCD have increased, so has the risk of
transfusional iron overload, which has been associated with
morbidity and mortality in SCD (Ballas, 2001). Patients with
SCD show differences in iron metabolism and trafficking
compared with other haemoglobinopathies; in particular, the
effects of inflammatory cytokines in SCD may lead to increased
iron levels in reticuloendothelial, macrophage and renal cells,
resulting in different tissues and organs being affected by iron
overload in SCD (Walter et al, 2009). However, regularly
transfused patients with SCD still have increased liver iron
concentration (LIC), which has been shown to correlate
significantly with the volume and duration of transfusions;
increased LIC is also associated with liver fibrosis (Harmatz
et al, 2000; Olivieri, 2001; Brown et al, 2009). The number of
lifetime transfusions has also been correlated with other
markers of iron overload, such as non-transferrin-bound iron
and serum ferritin levels (Inati et al, 2011). Furthermore,
despite patients who are chronically transfused for longer
periods being less likely to be hospitalized over a 12-month
period, in those patients who were hospitalized, a positive
correlation was observed between serum ferritin and hospital-
ization frequency (Fung et al, 2007).
Consequently, guidelines such as those in the USA and UK
currently recommend initiating iron chelation therapy in
patients with SCD once LIC increases to ‡7 mg Fe/g dry
weight, if serum ferritin steady state levels are >1000 lg/l, or if
patients have received cumulative transfusions of 120 cc packed
red blood cells/kg (USA) or at least 20 top-up transfusions
(UK) (National Institutes of Health NHLBI, 2002; Sickle Cell
Society, 2008). However, safety and efficacy data have yet to be
reported from large prospective clinical trials of any iron
chelator in patients with SCD beyond 1 year of follow-up.
Deferasirox is a once-daily, oral iron chelator that has been
shown to efficaciously reduce iron burden with a clinically
manageable safety profile in patients with b-thalassaemia and
other transfusion-dependent anaemias (Cappellini et al, 2006;
Cappellini et al, 2010; Porter et al, 2008). During a 1-year,
randomized, open-label, Phase II clinical trial, deferasirox
demonstrated comparable efficacy to deferoxamine (DFO) and
acceptable tolerability in iron-overloaded adult and paediatric
patients with SCD (Vichinsky et al, 2007). Patients completing
this 1-year core study were eligible to enter a 4-year extension.
Cumulative 5-year safety and efficacy data of iron chelation
therapy with deferasirox in transfusion-dependent patients
with SCD are reported here.
Methods
Study design and patient population
Male and female patients with SCD aged ‡2 years and with
transfusional iron overload were enrolled into the initial core
study according to the inclusion/exclusion criteria described
previously (Vichinsky et al, 2007). Patients who completed the
core study and had serum ferritin levels ‡500 lg/l could elect
to enter an extension study, which was initially intended to be
3 years, but was extended to 4 years after a protocol amend-
ment. Patients randomized to receive deferasirox in the core
study continued with deferasirox during the extension,
whereas those who received DFO during the core switched
to deferasirox treatment at the start of the extension. Patients
continued to receive blood transfusions according to their
regimen prior to study entry (chronic or intermittent simple
transfusion, or exchange transfusion). Treatment with any
regular medication required to treat concomitant conditions,
including hydroxycarbamide (hydroxyurea), was permitted
during the study.
Dosing
For patients randomized to deferasirox in the core study, the
dose at the start of the extension study was determined by
their serum ferritin trends during the core study. In patients
with stable or increasing serum ferritin trends, the initial
dose could be increased by 5 or 10 mg/kg per d, whereas the
dose was maintained in patients who had declining serum
ferritin trends during the core. In patients randomized to
DFO in the core study, initial deferasirox dose was deter-
mined by the treating investigator according to the following
guidelines: an initial dose of 20 mg/kg per d was recom-
mended for patients receiving 2–4 units/month (or 7–14 ml/
kg per month) of packed red blood cells, although initial
doses of 10 or 30 mg/kg per d could be considered for
patients with lower or higher transfusion requirements,
respectively. During the extension study, dose adjustments
in increments of 5 or 10 mg/kg per d were allowed every
3 months based on trends in serum ferritin levels and safety
parameters.
Assessments
All adverse events (AEs) and serious AEs were monitored
and recorded regularly by investigators. Details of AEs and
their management are reported in accordance with the
information provided by the investigating clinician. Labora-
tory parameters, including haematology, blood chemistry,
urine, liver function and renal function analyses were
monitored at least monthly; samples were processed at a
central laboratory. Assessment of vital signs (height, weight,
sitting pulse and sitting blood pressure), auditory and visual
functions were regularly performed. In paediatric patients
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(aged 2–<16 years), additional assessments included those of
stature, growth velocity and pubertal development according
to Tanner staging (Marshall & Tanner, 1969, 1970).
Individual growth curves of paediatric patients were plotted
based on the Centers for Disease Control and Prevention
growth charts for the US (Kuczmarski et al, 2000). Efficacy
was evaluated by monthly measurement of serum ferritin
levels.
Statistical analysis
Safety and efficacy data are reported for all patients who
received at least one dose of deferasirox during the core or
extension studies, unless otherwise stated. The statistical
significance of differences in serum ferritin levels from start
of deferasirox treatment to end of study was determined using
the two-sided Sign test at the significance level a 0Æ05. Serum
ferritin values are reported as median (range). Changes in
serum ferritin are reported as median [95% confidence
intervals (CI)]. Serum ferritin values at the start of deferasirox
for patients who received deferasirox during the core study
were taken as the mean of all available pretreatment values. For
patients who received DFO during the core study, the mean of
the last three available serum ferritin level assessments prior to
starting deferasirox was used. Reported end-of-study values for
serum ferritin represent the average of the last three available
assessments after the start of deferasirox. Average iron intake
was derived from the monthly blood intake using the formula:
average iron intake (mg/kg/d) = average blood intake (ml/kg/
month) · 1Æ08/28 days. Average iron intake and average actual
dose are reported as mean ± SD. Creatinine clearance was
calculated based on the serum creatinine level and the last
available height and weight measurement prior to the sample
date, using the Schwartz formula (Schwartz et al, 1987) for
paediatric patients and the Cockcroft–Gault formula (Cock-
croft & Gault, 1976) for adult patients.
Results
Study population
One hundred and ninety-five patients were initially enrolled at
44 sites in Canada, France, Italy, the UK and the USA; 173
completed the core and 163 entered the extension study.
Patients who chose not to enter the extension did not have to
explain their reasoning. Overall, 185 patients received at least
one dose of deferasirox between 27 May 2003 (first patient
enrolled) and 31 July 2009 (last patient, last visit). Patient
demographics at the start of deferasirox treatment, corre-
sponding to core baseline or start of the extension in patients
initially randomized to deferasirox or DFO, respectively, are
summarized in Table I. Ninety of 185 patients (48Æ6%) treated
with deferasirox were aged <16 years.
The 5-year study was completed by 62 patients (33Æ5%)
overall. In total, 71 patients (38Æ4%) discontinued after
withdrawing consent (specific reasons for this were not
reported), administrative problems or were lost to follow-up.
These patients accounted for the majority (57Æ7%) of the 123
who discontinued. Discontinuation as a result of AEs was
reported in 14 (7Æ6%) patients overall (Table II).
Of the 61 patients who withdrew consent or were lost to
follow-up, nine (14Æ8%) reported AEs within 2 weeks prior to
study discontinuation. The AEs were predominantly mild in
severity (Table III) and none were suspected to be related to
deferasirox treatment.
Deferasirox dosing and exposure
During the study, patients received an average actual deferasi-
rox dose of 19Æ4 ± 6Æ3 mg/kg per d and the median duration of
deferasirox treatment was 36Æ9 months.
Table I. Patient demographics at the start of deferasirox treatment.
Characteristic All patients (n = 185)
Mean age (range), years 19Æ2 (3Æ0–54Æ0)
Age group, n (%)
<6 years 5 (2Æ7)
6–<12 years 42 (22Æ7)
12–<16 years 43 (23Æ2)
16–<50 years 91 (49Æ2)
50–<65 years 4 (2Æ2)
Male:female, n 74:111
Caucasian:black:other, n 11:167:7
History of splenectomy, n (%) 24 (13Æ0)
Median serum ferritin (range), lg/l 3329 (405–12,901)
Serum ferritin, n (%)
500–1000 lg/l 3 (1Æ6)
>1000–2500 lg/l 61 (33Æ0)
>2500–4000 lg/l 48 (25Æ9)
>4000 lg/l 73 (39Æ5)
Table II. Patient disposition after the start of deferasirox treatment.
Disposition, n (%) Patients (n = 185)
Completed 62 (33Æ5)
Discontinued 123 (66Æ5)
Adverse events 14 (7Æ6)
Abnormal laboratory value/test procedure 6 (3Æ2)
Unsatisfactory therapeutic effect 6 (3Æ2)
No longer requires study drug 9 (4Æ9)
Protocol violation 3 (1Æ6)
Subject withdrew consent 44 (23Æ8)
Lost to follow-up 17 (9Æ2)
Administrative problems 10 (5Æ4)
Death 3 (1Æ6)
Stopped at end of core 7 (3Æ8)
Stopped at end of extension 1* 4 (2Æ2)
*Completed 3-year extension study before extension was prolonged to
4 years by protocol amendment
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Safety and tolerability
The most common AEs reported in >40% of patients overall
were headache (n = 94, 50Æ8%), sickle cell crisis (n = 91,
49Æ2%) and pyrexia (n = 83, 44Æ9%). Sickle cell crisis leading to
hospitalization was reported in 64 patients (34Æ6%). Pyrexia
was reported on the same day as sickle cell crisis in 15 patients
(8Æ1%). Ninety-three patients (50Æ3%) reported AEs that
investigators suspected to be study drug-related; the most
frequently reported (‡5% overall) are listed in Table IV (all
investigator-assessed drug-related AEs are listed in Table SI).
These were mostly gastrointestinal disorders that were mild-to-
moderate, transient in nature and decreased in frequency after
the first year (Fig 1). Three patients discontinued the study as a
result of gastrointestinal disorders with a suspected relation-
ship to deferasirox treatment [abdominal pain (n = 1), acute
pancreatitis (n = 1) and diarrhoea (n = 1)].
Serious AEs were experienced by 131 patients (70Æ8%)
overall. The most common serious AEs, which were reported
in ‡10% of all patients, were sickle cell crisis (n = 67, 36Æ2%)
and pyrexia (n = 34, 18Æ4%). Deferasirox was permanently
discontinued in 12 patients (6Æ5%) following serious AEs. Nine
patients (4Æ9%) had 17 serious AEs that investigators suspected
to be related to deferasirox treatment, including gastrointes-
tinal disorders (n = 3), sickle cell crisis (n = 2), lymphade-
nopathy (n = 1), tinnitus (n = 1), granuloma (n = 1),
tuberculosis (n = 1), spontaneous abortion (n = 1), pulmo-
nary thrombosis (n = 1), increased alanine aminotransferase
(ALT; n = 1), increased aspartate aminotransferase (AST;
n = 1), increased blood alkaline phosphatase (n = 1),
increased blood amylase (n = 1), increased blood bilirubin
(n = 1), increased lipase (n = 1) and increased transaminases
(n = 1). Neither of the patients who had sickle cell crisis with a
suspected relationship to deferasirox was receiving the drug at
the time of the event. No action with respect to deferasirox
dosing was taken following the case of spontaneous abortion;
the patient received 20 mg/kg per d deferasirox throughout the
extension until discontinuation as a result of an AE (otitis
media, not suspected to be related to deferasirox treatment).
AEs led to deferasirox dose adjustment or interruption in
107 patients (57Æ8%; Table SII); serious AEs led to dose
adjustment or interruption in 65 patients (35Æ1%). Dose
adjustments and interruptions were primarily a result of
gastrointestinal adverse reactions (n = 38, 20Æ5%). Increases in
serum creatinine levels (reported by investigators as an AE) led
to dose adjustment or interruption in 11 (5Æ9%) patients
overall. Data were available for 37 patients before and after
deferasirox dose increases to >30 mg/kg per d during the
study; exposure to doses £30 mg/kg per d and >30 mg/kg per
d was 98Æ3 and 50Æ9 patient years, respectively. There were no
apparent differences in the incidence or type of AEs before and
after the dose increased above 30 mg/kg per d. Similarly, there
were no clinically meaningful differences in renal or liver
laboratory parameters assessed before and after dose increases
above this threshold.
There were three deaths during the study. One patient died
as a result of intracranial haemorrhage following a liver
transplantation. This patient had underlying liver disease
secondary to hepatitis C, in addition to haemosiderosis. After
receiving deferasirox for approximately 40 months, the patient
was diagnosed with hepatic failure, which was assessed as
related to the underlying disease and not to the study drug.
Ten days after discontinuing deferasirox as a result of the
hepatic failure, as well as associated renal failure, the patient
Table III. AEs after start of deferasirox within 2 weeks prior to dis-
continuation due to withdrawal of consent or loss to follow-up.
AE, n (%) Patients (n = 185) Severity
Any AE 9 (4Æ9) –
Influenza 1 (0Æ5) Moderate
Nasopharyngitis 1 (0Æ5) Mild
Staphylococcal infection 1 (0Æ5) Moderate
Pain in extremity 2 (1Æ1) Mild/moderate
Back pain 1 (0Æ5) Mild
Sickle cell crisis 1 (0Æ5) Severe
Ear pain 1 (0Æ5) Mild
Pyrexia 1 (0Æ5) Mild
Excoriation 1 (0Æ5) Mild
Increased c-glutamyltransferase 1 (0Æ5) Mild
Table IV. Most common (‡5% overall) investigator-assessed drug-
related adverse events after the start of deferasirox.
Adverse event, n (%)
All patients
(n = 185)
Nausea 27 (14Æ6)
Diarrhoea 20 (10Æ8)
Increased serum creatinine* 11 (5Æ9)
Vomiting 10 (5Æ4)
Abdominal pain 9 (4Æ9)
*Increase in serum creatinine assessed by investigators to be clinically
significant and reported as an adverse event (AE). No specific
parameters were defined for reporting laboratory assessments as AE.
Fig 1. Yearly frequency of most common (‡5% overall) investigator-
assessed drug-related AEs after the start of deferasirox. *Reported as an
AE by the investigator.
E. Vichinsky et al
390 ª 2011 Blackwell Publishing Ltd, British Journal of Haematology, 154, 387–397
underwent a liver transplantation. The day following the
transplantation the patient died as a result of an intracranial
haemorrhage. The other two deaths were both due to
intraventricular haemorrhage. One patient had a history of
transient ischaemic attack and cerebrovascular accident, while
the other had Moyamoya disease at the time of enrolment.
None of the three deaths was suspected to be related to
treatment with deferasirox.
Renal parameters. Calculated creatinine clearance remained
stable during deferasirox treatment for up to 5 years (Fig 2).
Two patients (1Æ1%) reported reduced creatinine clearance in
the >40–£60 ml/min range. No patients had a reduction of
creatinine clearance to <40 ml/min at two consecutive
assessments. Ten patients (5Æ4%) presented with serum
creatinine values greater than the upper limit of normal
(ULN) and >33% above the value at the start of deferasirox
treatment on two consecutive visits during the study: all had
serum creatinine levels below the upper limit of normal (ULN)
at the start of deferasirox treatment except for one who had
received DFO during the core study. This patient had
presented with these criteria on multiple occasions while
receiving DFO but successfully completed the extension while
taking deferasirox; serum creatinine levels were mostly stable
during the extension. Two patients discontinued deferasirox
because of abnormal renal parameters and one discontinued
for reasons that were unclear from the information provided.
In three patients, serum creatinine levels normalized following
temporary interruptions to deferasirox treatment and these
patients went on to complete the study. The remaining three
patients completed the study without dose decreases or
interruption in response to increases in serum creatinine
levels >33% above levels at the start of deferasirox and >ULN;
serum creatinine levels returned to normal range in one patient
and remained elevated in the other two patients. Acute renal
failure was reported in two patients (1Æ1%) in the deferasirox
cohort; both events were assessed to be due to the patients’
underlying condition. In one of these patients, serum creatinine
levels were elevated to 123Æ8 lmol/l and a computed
tomography scan revealed a haemorrhagic cyst of the left
kidney. Deferasirox was discontinued because of acute renal
failure and simultaneous hepatic failure. The patient’s
subsequent death as a result of intracranial haemorrhage,
post-liver transplantation, is described above. In the second
patient, serum creatinine levels increased to 97Æ2 lmol/l during
an episode of acute chest syndrome and pneumonia.
Deferasirox was continued without alteration and the acute
renal failure resolved following concomitant treatment (infusion
of normal saline) and the patient completed the study. Three
patients (1Æ6%) had notable abnormalities in total urinary
protein:creatinine ratio (>1Æ0 mg/mg) at two consecutive
assessments. In two patients, proteinuria resolved following a
temporary dose interruption. The third patient was not
receiving deferasirox at the time that the increased urinary
protein:creatinine ratio was recorded. There were no reported
cases of serious tubular damage (Fanconi syndrome) during
deferasirox treatment.
Hepatic parameters. Five patients (2Æ7%), had increased ALT
values >5 · ULN on two consecutive assessments during
treatment with deferasirox; all had ALT levels >ULN prior to
entering the study. A further two patients (1Æ1%) had ALT
values >10 · ULN at two consecutive visits, one at day 582
while receiving 20 mg/kg per d and one at day 932 while
receiving 40 mg/kg per d; prior to commencing deferasirox
treatment, ALT levels were <ULN in both these patients. ALT
levels returned to the normal range in both patients following
a temporary interruption in deferasirox treatment and
remained at normal levels when the medication was
restarted until end of study. Overall, median ALT and AST
levels remained constant at normal levels throughout the
study. Hepatic failure was reported in one of the five patients
with two consecutive ALT values >5 · ULN; when admitted
to hospital, ALT and AST levels were elevated to 64 and
Fig 2. Quarterly creatinine clearance assessments after start of deferasirox treatment. Boxes define the interquartile range. Whiskers extend to the 10
and 90th percentiles. The line connects the median values.
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124 U/l respectively. Total bilirubin level was 83Æ8 lmol/l and
direct bilirubin was 59Æ8 lmol/l. The patient had presented
with hepatitis C and abnormal liver function tests at the time
of enrolment and hepatic failure was not suspected to be
related to deferasirox treatment. Deferasirox was discontinued
following diagnosis of hepatic failure and the patient
underwent liver transplantation. The death of this patient
as a result of intracranial haemorrhage post transplantation is
described above. Hepatic cirrhosis was reported as a serious
AE in one patient and as an AE in a further two patients; the
event was not suspected to be related to deferasirox
treatment.
Renal and hepatic parameters in patients who received
concomitant hydroxycarbamide. Twenty patients received
concomitant hydroxycarbamide during the study, of whom
one experienced increases in serum creatinine >33% above the
value at the start of deferasirox and >ULN at two consecutive
assessments and one had increases in ALT >5 · ULN at two
consecutive visits.
Other safety parameters. Neutropenia, defined as absolute
neutrophil counts <1Æ5 · 109/l at two consecutive
assessments after the start of deferasirox, was reported in one
patient (0Æ5%). The patient was not receiving deferasirox at the
time of the reported neutropenia as serum ferritin levels were
<500 lg/l.
Thrombocytopenia, defined as platelet counts <100 · 109/l
at two consecutive assessments after the start of deferasirox,
was reported in three patients (1Æ6%). In one of these patients,
deferasirox was discontinued prior to death because of
intracranial haemorrhage post-liver transplantation (as
described above). Thrombocytopenia resolved without alter-
ation of deferasirox treatment in the other two patients, who
both completed the study.
Mild lenticular opacities, suspected by investigators to be
related to the study drug, were reported in two patients (1Æ1%).
These events were reported during the core phase in both eyes
in one patient and during the third year of deferasirox
treatment in the right eye of the other patient. Deferasirox dose
was 20 and 30 mg/kg per d, respectively, in these patients at
time of onset. No action was taken with respect to deferasirox
treatment. The condition resolved after 211 days in the first
patient, who continued the study until the fifth year, then
withdrew consent. The second patient completed the study
despite ongoing lenticular opacity.
Nine patients (4Æ9%) had clinically significant audiometric
test abnormalities at the start of deferasirox; three of these
patients reported normal results during the study. A further
nine patients who had normal audiometric test results at the
start of deferasirox developed audiometric test abnormalities
during deferasirox treatment. These changes were often
transient despite continuation of deferasirox treatment; of
the nine patients who developed new, clinically significant
audiometric test abnormalities during the study, four contin-
ued to present with these abnormalities at the end of study. No
action was taken with respect to deferasirox treatment
following clinically significant audiometric test abnormalities.
Gastrointestinal haemorrhage was reported in two patients
(1Æ1%) but neither case was suspected to be related to
treatment; these events resolved following medical interven-
tion, and treatment with deferasirox was either continued or
temporarily interrupted during the event. Rash (of all types)
was reported as an AE in 36 patients (19Æ5%) overall, but was
only suspected to be related to deferasirox treatment by
investigators in seven patients (3Æ8%). One patient (0Æ5%)
discontinued deferasirox as a result of rash that investigators
assessed to be drug related.
Growth and development in paediatric patients. Steady
increases in weight and height were noted for 90 paediatric
patients aged 2–<16 years. Individual growth curves
demonstrated continuous growth of paediatric patients
during the study in line with normal trends derived from US
clinical growth charts; the majority of paediatric patients
demonstrated growth within the 5–95th percentile range.
Sexual development, as assessed by Tanner staging for breast
development and pubic hair in females and for testes volume
and pubic hair in males, progressed as expected for adolescent
patients.
Efficacy
Patients continued on their regular transfusion regimen
during the study and mean overall iron intake remained
relatively stable, with most patients receiving <0Æ3 mg/kg per d
of iron during up to 5 years of deferasirox treatment. For
patients who remained in the study, serum ferritin levels
steadily decreased with deferasirox treatment for up to 5 years,
with the largest decreases observed after the average actual
deferasirox dose increased above 20 mg/kg/d (Fig 3). In
patients who received deferasirox for at least 4 years, median
serum ferritin levels decreased significantly from 3410 lg/l
(1082–10,451 lg/l) at the start of deferasirox to 3108 lg/l (88–
14,743 lg/l) at end of study; the median absolute change in
serum ferritin was )591 lg/l (95% CI, )1411, )280 lg/l;
P = 0Æ027; n = 67). For all patients who received at least one
deferasirox dose, median serum ferritin levels were 3329 lg/l
(405–12,901 lg/l) at start of deferasirox and 3351 lg/l
(34–14,743 lg/l) at end of study using last observation carried
forward analysis.
The relative decrease in serum ferritin was greater in adult
than in paediatric patients. Paediatric patients were initiated
on lower deferasirox doses than adult patients (mean average
actual dose in months 0–3 was 15Æ6 ± 6Æ4 mg/kg per d in
paediatric patients and 16Æ4 ± 6Æ7 mg/kg per d in adult
patients). Paediatric patients, who had a higher annual mean
iron intake than adult patients, required increases in average
actual deferasirox dose to ‡25 mg/kg per d to achieve a median
relative decrease in serum ferritin levels after starting deferasi-
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rox, whereas relative decreases in serum ferritin were observed
in adult patients at doses of 20 mg/kg per d (Fig 4).
For patients with an available end of study (last observation
carried forward) serum ferritin change, 81 of 142 (57Æ0%)
patients in the <0Æ3 mg/kg per d mean overall iron intake
category and 19 of 34 (55Æ9%) patients in the 0Æ3–0Æ5 mg/kg
per d mean overall iron intake category had decreases in serum
ferritin levels of ‡10% from start of deferasirox treatment to
end of study (last day on deferasirox). Two patients had mean
overall iron intakes of >0Æ5 mg/kg per d; both had decreases in
serum ferritin levels of ‡10% from start of treatment to end of
study.
Discussion
In patients with SCD, transfusion therapy is frequently
initiated in childhood for the prevention of primary and
secondary stroke and may be indicated for continued use in
adults at high risk of progressive pulmonary, heart, renal and
brain injury (Vichinsky, 2001; National Institutes of Health
NHLBI, 2002; Wun & Hassell, 2009). The increased life
expectancy of patients with SCD has subsequently led to a need
for long-term iron chelation therapy to prevent the onset of
complications associated with iron overload, but long-term
iron chelation data in SCD are currently limited. This is the
largest study to date to assess the long-term safety and efficacy
of an iron chelator, deferasirox, in patients with SCD.
Of the patients who received at least one dose of deferasirox,
62 (33Æ5%) completed the extension study. The lack of data
from similarly long-term, prospective clinical trials in SCD
makes it difficult to assess the significance of the high
discontinuation rate with respect to deferasirox treatment.
More than half of the total discontinuations were recorded as
withdrawal of consent, loss to follow-up or administrative
problems, while only 14Æ1% were due to factors related to
therapy (AEs, abnormal laboratory value/test procedure or
unsatisfactory therapeutic effect). Only nine of 61 patients who
discontinued because of withdrawal of consent or loss to
follow-up experienced AEs within 2 weeks prior to discontin-
uation. The majority of these AEs were mild in severity and
none were suspected to be related to deferasirox treatment,
suggesting that adverse reactions to the study drug were
unlikely to contribute to study discontinuation in these
patients. Furthermore, the rates of discontinuation during
the 1-year core phase of the study were similar for patients
randomized to DFO or deferasirox (Vichinsky et al, 2007). A
similar profile of reasons for discontinuation, i.e, primarily for
reasons other than AEs, has been observed in several shorter-
term SCD clinical trials of hydroxycarbamide (Charache et al,
1992; Kinney et al, 1999; Steinberg et al, 2003). Meanwhile, a
similarly designed long-term study of deferasirox in patients
with b-thalassaemia for up to 5 years reported a completion
rate approximately double to that observed for this study
(Cappellini et al, 2009). Combined, these observations suggest
that disease and social factors specific to SCD patient
populations may contribute substantially to low study
completion rates.
The most frequently reported AEs in this study, such as
headache, sickle cell crisis and pyrexia, were either non-specific
or considered to be reflective of the underlying SCD rather
than of the study drug. As the study design did not include a
control arm, it is not possible to assess the impact of the
deferasirox treatment on the frequency of sickle cell crises;
however, none of the patients interrupted or discontinued
deferasirox because of an apparent increase in SCD activity.
During the core phase of the study, the frequency of sickle cell
Fig 3. Median relative change in serum ferritin levels and average actual deferasirox dose. Three-monthly values include the last available serum
ferritin assessment/dose available for that 3-month period. SD, standard deviation.
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crisis was comparable in patients randomized to deferasirox
(33Æ3%) and DFO (31Æ7%), suggesting that incidence is
comparable irrespective of chelator type (Vichinsky et al,
2007). High frequencies of sickle cell pain events, particularly
in an outpatient context, have been demonstrated by diary
studies (Smith et al, 2008), whereas data from the Stroke
Prevention Trial (STOP) have demonstrated that transfusions
only lead to significant reduction in pain events when
aggressive, chronic regimens are strictly complied with (Miller
et al, 2001).
AEs suspected to be related to deferasirox treatment were
predominantly gastrointestinal, transient and mild-to-moder-
ate in nature, as observed in the core study and trials of
deferasirox in other transfusion-dependent anaemias (Cappel-
lini et al, 2006; Porter et al, 2008; Cappellini et al, 2010;
Vichinsky et al, 2007). The incidence of rash with a suspected
relationship to deferasirox was lower in this study than in
other deferasirox trials, although the reason for this is unclear.
The frequency of the most common drug-related AEs generally
decreased year-on-year, suggesting that tolerability to defer-
asirox improves with long-term treatment. Although the
number of patients is limited (n = 37), it is encouraging to
note that, following dose increases to ‡30 mg/kg per d, there
was no apparent change in the safety profile, in line with
previous studies (Taher et al, 2009).
The prescribing information for deferasirox notes a risk of
renal and hepatic impairment, including failure, and gastro-
intestinal haemorrhage (predominantly in patients with
(B)
(A)
Fig 4. Median relative change in serum ferritin levels from start of deferasirox treatment and average actual deferasirox dose in (A) paediatric and (B)
adult patients. Three-monthly values include the last available serum ferritin assessment/dose available for that 3-month period. SD, standard
deviation.
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myelodysplastic syndromes). Renal failure, hepatic failure and
gastrointestinal haemorrhage were reported in a very small
number of cases during the present study and in each case
investigators believed the event to be related to patients’
underlying co-morbidities rather than deferasirox treatment.
The kidney, as a site of deferasirox toxicity, is of particular
relevance to patients with SCD who frequently present with
abnormal renal function. Creatinine clearance was relatively
stable throughout the study in both cohorts and most of the
notable increases in serum creatinine were managed without
the need to permanently discontinue deferasirox treatment.
Disease-related factors may reduce the sensitivity of serum
creatinine and creatinine clearance assessments in evaluating
renal function in patients with SCD; however, urinary
protein:creatinine ratio was also assessed during the study
and notable abnormalities were only reported in three patients.
Few patients presented with abnormal ALT levels and signif-
icant elevations were transient and manageable. The onset of
AEs and clinically significant changes in laboratory parameters
did not appear to be related to deferasirox dose or length of
exposure.
Almost half of the patients included in this analysis were
paediatric patients aged <16 years. Paediatric patients with
SCD often have retarded growth and delayed sexual matura-
tion (Platt et al, 1984), which may be normalized by long-term
transfusion therapy (Wang et al, 2005). During long-term
deferasirox treatment, most paediatric patients had normal
growth compared to a standard US population and sexual
development also progressed without evidence of significant
delay. As such, the benefits of transfusion on paediatric growth
and development in patients with SCD do not seem to be
impeded by long-term treatment with deferasirox.
In all patients who completed at least 4 years of deferasirox
treatment, the median serum ferritin level was significantly
reduced. However, the conservative dosing regimen adopted
at the start of deferasirox treatment meant that overall
median serum ferritin levels did not decrease below baseline
during the first 2 years, when the average actual dose was
<20 mg/kg per d. This trend was prolonged in paediatric
patients, in whom median serum ferritin levels remained at
or above the levels reported at the start of deferasirox for
3 years. This could be reflective of the low initial dosing of
deferasirox in paediatric patients during the core study,
despite generally higher mean overall iron intake compared
with adults, thus suggesting a similar relationship between
iron intake and response to a given deferasirox dose to that
reported in a b-thalassaemia study (Cohen et al, 2008). The
pharmacokinetic profile of deferasirox is such that the steady-
state exposure is lower in paediatric patients than in adults,
meaning paediatric patients with SCD may require higher
doses to achieve effective iron chelation (Galanello et al,
2006). Efficacy results should also be interpreted with the
consideration that start of deferasirox represents different
time points in the study depending on whether patients were
randomized to receive deferasirox or DFO during the core
phase. Fifty-three of the 185 patients included received DFO
under controlled trial conditions during the first year of the
study; these patients received deferasirox for a maximum of
4 years, rather than 5 years, and had generally lower serum
ferritin levels at the start of deferasirox treatment compared
with those randomized to receive deferasirox from the onset
of the study.
Assessment of the efficacy of deferasirox in reducing iron
burden was limited to serum ferritin analysis in this study.
Serum ferritin levels can be influenced by inflammatory
processes (Piperno, 1998), which are often exacerbated in
patients with SCD because of vaso-occlusive crisis and
haemolysis, as well as infection (Brittenham et al, 1993).
Inflammatory responses indicate that patients with SCD have
higher levels of cytokines, which affect the synthesis of ferritin
and its release into the circulation (Walter et al, 2006). Serum
ferritin levels in patients with SCD have shown varying degrees
of correlation with LIC, which is considered a more direct
measure of iron overload, depending on the methods of LIC
assessment (Brittenham et al, 1993; Karam et al, 2008).
Although LIC was not assessed during the extension, the
maintenance of overall ALT and AST at normal levels
throughout the study suggests that liver function did not
decrease during deferasirox treatment. Such considerations are
important when evaluating iron overload, deferasirox efficacy
and dosing strategy specifically in patients with SCD. Iron
loading patterns differ in patients with SCD compared with
thalassaemia major, not only as a result of disease-associated
factors, including chronic inflammation and intravascular
haemolysis (Porter, 2009), but also because of different
transfusion regimens and frequencies in patients with SCD,
which give them a unique iron intake profile.
In conclusion, long-term iron chelation therapy with
deferasirox was associated with a manageable safety profile
and did not significantly affect kidney function in most adult
and paediatric patients with SCD during this study. In patients
with SCD who remain on the treatment regimen, deferasirox
with appropriate dosing represents an effective long-term
treatment to accompany ongoing transfusion therapy, facili-
tating the prevention of stroke and organ failure by potentially
reducing the risk of developing complications of iron overload.
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